Leah SibenerHead of Therapeutic Discovery, Co-Founder at 3T Biosciences, USA
Profile
Leah is a co-founder and VP and Head of Therapeutic Discovery at 3T Biosciences. At 3T she leads the R&D operations and strategy focusing on identifying new immunotherapy targets, and engineering T cell receptor based therapeutics. Leah has co-authored work in high-impact journals such as Cell, Science, Nature Immunology, Immunity, Elife, Nature Genetics, and PNAS. She holds a Bachelor’s degree in Biophysics from Johns Hopkins University, and a PhD in Immunology from Stanford University where she developed 3T’s target discovery platform in Chris Garcia’s research group. She was named one of Forbes’ 2018 30-under-30 in Healthcare. Prior to Stanford and 3T, Leah was a part of research teams at the Johns Hopkins Institute for Cellular Engineering in Jonathan Schneck’s Lab, as well as at Genentech in Early Discovery Immunology.
Agenda Sessions
Modification of CART Cells to Improve Efficacy and Epitope Spreading
, 9:45amView Session